Nikhil Chopra, CEO & Whole-time Director, J.B. Chemicals & Pharmaceuticals Limited, said, "Being one of leaders in the hypertension segment, we realised that Chronic Kidney Disease is a major issue in the country and the numbers are rising significantly. There are growing cases of hypertension associated with CKD and we believe this initiative will enable us service the growing unmet needs of CKD patients.”
Chopra added, "JBCPL remains committed to serving the needs of patients and the launch of the dedicated nephrology division is a testament to that fact. Besides the division launch, we will continue to create awareness about CKD and enable patients to reach out to physicians as early as possible.”
With the launch of this new division and patient-centric initiatives, JBCPL can help address the medical needs of patients with CKD. The launch of this division will also enable nephrologists and physicians to provide patients with different treatment options and ultimately improve the quality of life in these patients.
As per the regulatory filing, the new division will focus exclusively on comprehensive renal care ranging from the management of hypertension in Chronic Kidney Disease to End-stage renal disease. After successfully becoming one of the leading players in Hypertension with brands like Cilacar and Nicardia, JBCPL has now begun to also focus on patients with CKD
The company will continue to launch products under this division to achieve its objective of providing holistic support to CKD patients at every stage.
On Sensex, the company stock finished at Rs1445.45 per piece up 2.06%.